Webb10 Feb 2024 Kechow Pharma plans a phase IIa/IIb trial for Colorectal cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in China (PO), in February 2024 , (NCT05233332) 20 Dec 2024 HL 085 is still in phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in ... WebbKeChow Pharma is a company that provides Drug discovery, Medicine and more. KeChow Pharma is headquartered in China Shandong. KeChow Pharma was founded in 2014. KeChow Pharma has a total of 44 patent More
泰锟医药 您可信赖的临床药物管理专家 - Taikun Pharma
Webb12 juni 2024 · Shanghai Kechow Pharma, Inc. Provider of Information About this Clinical Study Sponsor Overall Official(s) Hongqi Tian, PhD, Study Director, Shanghai Kechow Pharma. Conditions in This Trial Nsclc Interventions in This Trial HL-085 Docetaxel Condition MeSH Term(s) Carcinoma, Non-Small-Cell Lung Intervention MeSH Term(s) … Webb4 jan. 2024 · HL-085 (Shanghai Kechow Pharmaceutical Research & Development Co., Ltd, Shanghai, China) was adminis - tered as 0.5 mg , 2.0 mg, and 6.0 mg capsules, twice daily how to skype video chat
First-in-human phase I dose-escalation and dose-expansion trial of …
WebbAddress: Room 3M, Floor 3, No.780, Cailun Road, Pudong New District Shanghai, Shanghai, 201203 China See other locations Phone: ? Website: www.kechowpharma.com Webb17 juni 2024 · 首席赞助商: Shanghai Kechow Pharma, Inc. 资源: Shanghai Kechow Pharma, Inc. 简要总结: 研究药物 HL-085 是一种 MEK 抑制剂,具有潜在的癌症适应症。它是一个 每日口服药物。 本研究的目的是寻找以下研究问题的答案: 1. Webb21 aug. 2024 · Shanghai KeChow Pharma, Inc. is a clinical-stage biotech focusing on differentiated small molecule therapeutics for cancer. The company was founded by Dr. … nova teaching certificate